Venker Eric 4
4 · Roivant Sciences Ltd. · Filed Oct 17, 2025
Insider Transaction Report
Form 4
Venker Eric
President & Immunovant CEO
Transactions
- Sale
Common Shares
2025-10-15$16.93/sh−414,683$7,020,583→ 1,504,959 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-17−118,418→ 0 totalExercise: $15.85Exp: 2026-03-31→ Common Stock (118,418 underlying) - Exercise/Conversion
Common Shares
2025-10-15$15.85/sh+414,683$6,572,726→ 1,919,642 total - Exercise/Conversion
Common Shares
2025-10-16$15.85/sh+318,282$5,044,770→ 1,823,241 total - Sale
Common Shares
2025-10-16$17.05/sh−318,282$5,426,708→ 1,504,959 total - Exercise/Conversion
Common Shares
2025-10-17$15.85/sh+118,418$1,876,925→ 1,623,377 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-15−414,683→ 436,700 totalExercise: $15.85Exp: 2026-03-31→ Common Stock (414,683 underlying) - Sale
Common Shares
2025-10-17$17.06/sh−118,418$2,020,211→ 1,504,959 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-16−318,282→ 118,418 totalExercise: $15.85Exp: 2026-03-31→ Common Stock (318,282 underlying)
Footnotes (2)
- [F1]The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
- [F2]Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.